Stan Miele Email

President and Co-Founder . AQUALUNG THERAPEUTICS CORPORATION

Current Roles

Employees:
6
Revenue:
$930k
About
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung’s strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.
AQUALUNG THERAPEUTICS CORPORATION Address
1790 E River Rd
Tucson, AZ
United States
AQUALUNG THERAPEUTICS CORPORATION Email
AQUALUNG THERAPEUTICS CORPORATION Phone Numbers
630-802-0786

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.